Journal
MICROORGANISMS
Volume 10, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/microorganisms10101887
Keywords
visceral leishmaniasis; tropical diseases; neglected diseases; Leishmania; protozoa; pediatrics
Categories
Ask authors/readers for more resources
Visceral Leishmaniasis (VL) is a potentially lethal disease caused by a parasitic infection. The effectiveness of treatment may vary depending on the geographical area and the specific parasite species. Recent advancements in drug therapy have improved treatment outcomes for VL.
Visceral Leishmaniasis (VL) is a vector-borne disease caused by an intracellular protozoa of the genus Leishmania that can be lethal if not treated. VL is caused by Leishmania donovani in Asia and in Eastern Africa, where the pathogens' reservoir is represented by humans, and by Leishmania infantum in Latin America and in the Mediterranean area, where VL is a zoonotic disease and dog is the main reservoir. A part of the infected individuals become symptomatic, with irregular fever, splenomegaly, anemia or pancytopenia, and weakness, whereas others are asymptomatic. VL treatment has made progress in the last decades with the use of new drugs such as liposomal amphotericin B, and with new therapeutic regimens including monotherapy or a combination of drugs, aiming at shorter treatment duration and avoiding the development of resistance. However, the same treatment protocol may not be effective all over the world, due to differences in the infecting Leishmania species, so depending on the geographical area. This narrative review presents a comprehensive description of the clinical picture of VL, especially in children, the diagnostic approach, and some insight into the most used pharmacological therapies available worldwide.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available